Genmab A/S ADR (GMAB) News

Genmab A/S ADR (GMAB): $27.82

0.17 (-0.61%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add GMAB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#15 of 355

in industry

Filter GMAB News Items

GMAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GMAB News Highlights

  • For GMAB, its 30 day story count is now at 5.
  • Over the past 7 days, the trend for GMAB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about GMAB are ABBV, ASH and CR.

Latest GMAB News From Around the Web

Below are the latest news stories about GENMAB A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.

Genmab to Hold 2023 R&D Update and ASH Data Review Meeting

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 12, 2023 – Genmab A/S (Nasdaq: GMAB) will hold its 2023 R&D Update and ASH Data Review Meeting today, December 12, 2023 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast. To register for the webcast, click https://genmab-post-ash-2023.open-exchange.net/. An archive of the webcast will be avai

Yahoo | December 12, 2023

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

COPENHAGEN, Denmark, December 09, 2023--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR) rate of 63 percent and minimal residual disease (MRD) negativity rate of 67 percent in patients with relapsed/refractory (R/R) foll

Yahoo | December 9, 2023

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with two or more prior therapies experienced strong and durable responses with high overall response (ORR) and complete response (CR) rates when treated with epcoritamab (DuoBody® CD3xCD20), an investigational, subcutaneously administered T-cell engaging bispecific antibody. More than half of patients who responded to treatment in the st

Yahoo | December 9, 2023

HRMY or GMAB: Which Is the Better Value Stock Right Now?

HRMY vs. GMAB: Which Stock Is the Better Value Option?

Yahoo | December 7, 2023

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; December 5, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 7,054 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 1,106 shares at DKK 1,025.00,3,453 shares at DKK 1,145.00,300 shares at DKK 1,147.50,85 shares at DKK 1,161.00,7

Yahoo | December 5, 2023

AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag

The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.

Yahoo | November 28, 2023

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

COPENHAGEN, Denmark, November 27, 2023--Genmab A/S (Nasdaq: GMAB) today announced regulatory updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously. The U.S. FDA has granted Breakthrough Therapy Designation (BTD) to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemi

Yahoo | November 27, 2023

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish tradin

Yahoo | November 21, 2023

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,541 restricted stock units to members of the Board of Directors and employees of the Company as well as the Company’s subsidiaries and 7,651 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK

Yahoo | November 21, 2023

7 Must-Buy Stocks That Are on Ridiculous Discount Now

Given that this may be the year of artificial intelligence, it’s no surprise that while certain enterprises have hogged the spotlight, astute investors also enjoy compelling opportunities regarding stocks on sale.

Josh Enomoto on InvestorPlace | November 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!